week 1
pharmacology & toxicology
preclinical safety timeline
tragedies in drug safety
in vitro safety assays
risks from hERG channel inhibition
week 2
on-target toxicity
in vivo toxicology studies
drug-drug interactions
intra-family target selectivity
drug purity and safety
week 3
efficacy vs. safety risks
maximum recommended starting dose
safety in oncology drugs
preclinical safety concurrent with clinical trials
post-approval surveillance